Kornimate/medical-research-clean huggingface dataset:
automated icd coding of primary diagnosis based on machine learning

Conditions: Cardiovascular Diseases

Summary: this study aims to develop and validate machine learning model in icd-10 coding of primary diagnosis related to cardiovascular diseases in chinese corpus.

the accuracy and productivity of icd coding has always been a concern of clinical practice. errors of icd codes may result in claim denials and missed revenue. however, icd coding process is complex, time-consuming and error-prone. more experienced coders are in need, but there is an increasing lack of supply. automated icd coding has potential to facilitate clinical coders for improved efficiency and quality. model performance of related studies is still far below coders and both the accuracy and interpretability need to be improved in great demand. besides, studies in chinese corpus are not sufficient. in this study, the investigators will implement automated icd coding study based on inpatient' data collected from electronic medical records from fuwai hospital, the world's largest medical center for cardiovascular disease. feature engineering and machine learning methods will be used to develop classification models with good performance, interpretability and practicability for icd codes of primary diagnosis.

Eligibility criteria:
inclusion criteria: * admissions in fuwai hospital, from january 1, 2019, to december 31, 2020 exclusion criteria: * admissions stayed in nephrology department, fuwai hospital
posaconazole pharmacokinetics in patients receiving chemotherapy or stem cell transplants

Conditions: Posaconazole; Pharmacokinetics; Invasive Candidiases; Invasive Aspergillosis; Invasive Mycosis; Fungal Infection; Prophylaxis

Summary: the purpose of the study is to investigate the pharmacokinetics of oral dosage of posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.

participants receiving posaconazole prophylaxis for invasive fungal infection while undergoing cancer treatment will be required to sign an informed consent and donate blood samples for the study. posaconazole is routinely administered as a prophylaxis using the oral tablet formulation (300mg once daily) as a standard care. each prophylaxis course-duration will be defined according to local policy at each hospital. in general, posaconazole prophylaxis commences prior to or with induction or consolidation chemotherapy in aml/mds patients and continues until neutrophil recovery. in allo-hsct setting, posaconazole prophylaxis routinely commences on the day of transplant or with conditioning chemotherapy and continues for approximately 3 months after transplant, except in patients with initiation of intensive immunosuppression after diagnosis of acute or chronic gvhd, administration will go for at least 16 weeks or until prednisolone dose is less than 10mg per day, whichever is later. if patients are suspected or have proven malabsorption or are required to switch to an alternative antifungal agent such as in the case of suspected invasive fungal infection or posaconazole toxicity, a switch to intravenous formulation of posaconazole will take place. blood samples will be collected on days 7, 14 and 21 from the onset of posaconazole prophylactic treatment. if significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve, with the first sample being taken 3 days after the onset of diarrhoea. if gastrointestinal absorption is considered inadequate or invasive fungal infection is suspected and patients are switched either to iv antifungal prophylaxis or antifungal treatment as part of their standard care, a blood sample will be collected 20-24 hours after the last oral posaconazole dose. study participants will be followed up with respect to clinical data collection during the blood sample collection period and for up to 7 days after the last dose of posaconazole for invasive fungal infection follow-up, and for the entire antifungal prescribing period (prophylaxis and/or treatment). participants with diagnosed invasive fungal infection will be followed up to 30-days post-diagnosis with respect to clinical outcomes.

Eligibility criteria:
inclusion criteria: * adult (≥18 years old) haematology patients receiving posaconazole prophylaxis in the inpatient setting as standard of care. * able to give informed consent. exclusion criteria: * unable to give informed consent.
batch n ° 2 of the public market evaluation "medico-economic demonstrator isereadom"

Conditions: Heart Failure

Summary: the goal of this study is to evaluate the health and social benefit of innovative management - isereadom - versus conventional follow-up in patients with heart failure. there is a medico-economic goal too, is to perform a cost-utility analysis of the service bundle (isereadom) versus conventional 6-month community-based follow-up in a population with heart failure.


Eligibility criteria:
inclusion criteria: * patient diagnosed with heart failure confirmed by a cardiologist ; * patient with functional nyha ii, iii, iv staining ; * patient domiciled in the department of isère ; * patient who can be followed regularly for 6 months ; * patient who can benefit from resic-type health education ; * presence of a caregiver referent of proximity (family or other) according to appreciation of the investigating doctor in case of cognitive disorders ; * patient affiliated with social security or beneficiary of such a scheme ; * patient able to read, write and understand french ; * patient having signed informed consent to participate. exclusion criteria: * patient with peritoneal dialysis or haemofiltration ; * patient with severe co-morbidity with poor short-term prognosis: mortality \< 6 months ; * patient with future surgical etiologic treatment: prosthetic valve, revascularization procedure, tavi or mitraclip ; * patient residing in a nursing home or institution for dependent person ; * persons referred to in articles l1121-5 to l1121-8 of the csp (corresponds to all persons protected: pregnant woman, parturient, mother who is breastfeeding, person deprived of liberty by judicial or administrative decision, person subject of a legal protection measure).
pkc as serum biomarkers for depression

Conditions: Major Depressive Disorder

Summary: inflammation that is mediated by microglia activation plays an important role in the pathogenesis of depression. microglia activation can lead to an increase in the levels of proinflammatory cytokines, including tnf-α, which leads to neuronal apoptosis in the specific neural circuits of some brain regions, abnormal cognition, and treatment-resistant depression (trd). protein kinase c (pkc) is a key regulator of the microglia activation process. the investigators assume that the abnormality in pkc might be the serum biomarkers of depression.

pkc activation might reduce m1 microglia activation and the release of proinflammatory cytokines such as tnf-α, finally alleviating depressive symptoms in trd. primary objective: this study was designed to address the role of pkc-mediated microglial activation in the clinical outcome of first episode depression. secondary objective: to illustrate the impact of pkc-mediated microglial activation on impaired cognition, social function and neuronal plasticity. the investigators adopted randomized design to test placebo-controlled antidepressant augmentation. patients were randomized (1:1) into one of the following 2groups: "ssri +golimumab"," or "ssri +placebo". the total study duration is 12 weeks

Eligibility criteria:
inclusion criteria: * diagnosed with major depressive disorder (mdd) according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5); * insufficient response (response rate \<50%) to two antidepressants with different mechanisms when given for at least 6 weeks at an adequate dose (e.g., clomipramine ≥150 mg/d, fluoxetine≥20 mg/d) during the current episode; * a 17-item hamilton depression rating scale (hamd-17) score ≥ 17 no more than 7 days prior to randomization. cognitive factors (including a sense of guilt, suicidal thoughts, agitation, depersonalization, the disintegration of reality, paranoid symptoms, and obsessive and compulsive symptoms) score ≥6; ④ between 18 and 65 years of age; ⑤ education: finished junior middle school; ⑥ ethnicity: han chinese; * adequate audio and visual levels to complete the necessary checks; ⑧ compliance with treatment in the clinical trial. exclusion criteria: * severe liver and kidney diseases, active endocrine diseases or clinical symptoms. severe cardiovascular disease, respiratory system disease, hematologic diseases and cancer. * serious suicide attempts. * pregnancy or lactation. * modified electroconvulsive therapy (mect) therapy in the past 1 month. ⑤ known current psychosis as determined by the dsm-5 or a history of a non-mood psychotic disorder. * participation in another clinical trial concurrently or no more than 1 month prior to randomization. * previously had a severe allergic reaction or immune system disease; ⑧ using an anti-inflammatory drug or immunosuppressive agent; ⑨ hamd-17 item 3 (suicide) score: ≥3
early feasibility study of the "easy light" fluorecence imaging system

Conditions: Uterine Cervical Neoplasms; Uterine Neoplasms

Summary: this is an early feasibility study to evaluate the device functionality of an open-field handheld wireless fluorecence imaging system for detection of sentinel lymph nodes in women with cervical and uterine cancers who underwent open surgery.

this study was designed to clinically evaluate the functionality of an prototype of our near-infrared fluorescence device named easy light. in brief, this device is an open-field handheld wireless fluorecence imaging system that allows real-time visualization of fluorescent dyes such as indocyanine green (icg) using smartphones and tablets. the handheld is a rechargeable device responsible for excitation of the operative field with infra-red lighting and for capturing the fluorescence emitted by de fluorescent dye to be visualized via wi-fi in the smartphones and tablets using a pre-installed application software. following the standards of near-infrared fluorescence for detection of sentinel lymph nodes in gynecological malignancies, the hypothesis was the identification of sentinel lymph nodes after lymphatic mapping by interstitial indocyanine green injection in the cervix was feasible with the use of our device named easy light.

Eligibility criteria:
inclusion criteria: 1. patients with biopsy-proven cervical or uterine cancers; 2. clinical stage i or ii, according to figo - the international federation of gynecology and obstetrics; 3. indication for sentinel lymph node biopsy with or without complementary lymphadenectomy by her medical assistant; 4. performance status of 0-2; 5. no synchronous malignancies or previous oncological treatments such as radiation or major abdominal surgery; 6. absence of neuro-psychiatric disorders, apparent or confirmed infections, history of drug allergies, limiting obesity for surgery, and pregnancy or breast feeding; 7. appropriated cardio-respiratory, hepato-renal and hematological reserves; 8. signing of the consent form. exclusion criteria: 1. perioperative impossibility to inject the fluorescent dye indocyanine green in the cervical region due to any locorregional reason.

Keywords: sentinel lymph node biopsy fluorescence indocyanine green
a safer pre-natal diagnosis using free dna in maternal blood

Conditions: Aneuploidy, NIPT

Summary: a diagnostic peripheral maternal blood test taken and the free foetal dna is analysed and the presence of trisomies using a novel method.

a total of \~2000 participants have donated blood samples used for the development and validation of the iona non-invasive prenatal screening test for downs, edwards and patau syndrome. the iona test was ce marked feb 2013. we are now recruiting a further 800 participants to provide blood samples to further develop and verify the test for other chromosomal abnormalities and to improve test efficiency.

Eligibility criteria:
inclusion criteria: * patient/subject is willing and able to give informed consent for participation in the study. * female, aged 16 years or above. * currently pregnant at time of entry to the study. * pregnancy having been identified as 'high-risk' by screening test. exclusion criteria: * the patient/subject may not enter the study if any of the following apply: * the participant herself has down's syndrome or other chromosomal abnormality. * children under 16 * adults with learning disabilities * adults who are unconscious or very severely ill * adults who have a terminal illness * adults in emergency situations * adults suffering from a mental illness * adults with dementia * prisoners * young offenders * adults who are unable to consent for themselves * any person considered to have a particularly dependent relationship with investigators
home based environmental adherence trial

Conditions: Asthma; Lung Diseases

Summary: to conduct a randomized trial in asthmatic children to compare the effectiveness of a home-based allergen control program with a customary educational program delivered in offices

design narrative: two-hundred-forty children, 6 to 17 years of age, were recruited to participate in the study. following the collection of baseline data, all families in the study received standard environmental control education prior to randomization to the control or experimental group. this education provided parents and children with information about such topics as the child's sensitivity profile, the relationship between exposure to allergens and asthma, and the risks of passive smoking. all families were given information on how to receive environmental control aids and services available by mail at no or reduced costs. once families were randomized, those in the control group received no additional intervention. those in the experimental group received a home-based allergen control intervention delivered by trained environmental counselors. primary outcomes were changes in asthma-related quality of life and changes in targeted allergen levels in the home. secondary outcome measures included self-efficacy for environmental allergy control, fev1, and parent-reported health care utilization. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
long-term safety study of open-label pramipexole extended release (er) in patients with early parkinson´s disease (pd).

Conditions: Parkinson Disease

Summary: the general aim of this study is to obtain long-term safety and tolerability data on pramipexole er, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind study in early pd (248.524(nct00479401) or 248.636(nct00558025) trial).


Eligibility criteria:
inclusion criteria: 1. completion of the double-blind trial 248.524 or 248.636 2. male or female patient with early idiopathic parkinson´s disease (pd), and with a modified hoehn and yahr stage of i to iii. 3. patient willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. 4. signed informed consent obtained before any study procedures are carried out (in accordance with international conference on harmonisation (ich) - good clinical practice (gcp) guidelines and local legislation). exclusion criteria: 1. patients prematurely withdrawn from the double-blind trials 248.524 or 248.636. 2. atypical parkinsonian syndromes due to drugs,metabolic disorders, encephalitis or degenerative diseases. 3. any psychiatric disorder according to diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study.4.history of psychosis, except history of drug induced hallucinations. 5. clinically significant electrocardiogram (ecg) abnormalities at baseline. 6.clinically significant hypotension 7.malignant melanoma or history of previously treated malignant melanoma. 8.any other clinically significant disease, that could put the patient at risk or could prevent compliance or completion of the study. 9. pregnancy or breast-feeding. 10. sexually active female of childbearing potential not using a medically approved method of birth control for at least one month prior to the baseline and throughout the study.11 serum levels of aspartate aminotransferase (ast) (sgot), alanine aminotransferase (alt) (sgpt), alkaline phosphatase or bilirubin \> 2 upper limit of normal (uln) at baseline 12. patients with a creatinine clearance \< 50 ml/min (estimated by the cockcroft and gault formula). 13. motor complications under levodopa therapy (e.g. on-off phenomena, dyskinesia) at baseline. 14. any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit. 15.any of the following drugs within 4 weeks prior to baseline: methylphenidate, cinnarizine, amphetamines. 16. flunarizine within 3 months prior to baseline. 17. known hypersensitivity to pramipexole or its excipients. 18. drug abuse (including alcohol), according to investigator´s judgement, within 2 years prior to baseline. 19. participation in investigational drug studies other than trials 248.524 and 248.636 or use of other investigational drug within one month or five times the half-life of the investigational drug prior to baseline.
skin microbiome profile in hailey-hailey disease

Conditions: Hailey-Hailey Disease

Summary: "hailey-hailey disease is an autosomal dominant disorder caused by a genetic defect in a calcium atpase (atp2c1) leading to a defect in keratinocyte adhesion. the characteristic of this disease is the involvement of intertriginous areas of the skin, which are the moist sites including the axillary vault and the inguinal crease. the composition of microbial communities is primarily dependent on the physiology of the skin site and the moist sites have distinct compositions of skin microorganisms. in addition, treatment with doxycycline is often helpful in the management of hailey-hailey disease. these findings suggest a role of the skin microbiome in the pathogenesis of hailey-hailey disease. the purpose of this study is to characterize the skin microbiome in patients with hailey-hailey disease by the 16s method, to better understand the pathogenesis of the disease and to discover new therapeutic targets in the future.

investigators will look at patients with hailey-hailey disease, and healthy controls. investigators will look at skin microbiome (bacterial diversity and the relative abundance of major bacterial taxa) investigators will assess this in patients with hailey-hailey disease before and after doxycycline and compare them to healthy controls.

Eligibility criteria:
inclusion criteria: 1. hailey-hailey disease 1-1. inclusion criteria 1. clinically diagnosed with hailey-hailey as confirmed by histopathology and/or genetic analysis. 2. \>19 years old 3. patients who currently have lesions on the axilla and groin 4. patietns who signed the consent form and informed consent in human material research 2. normal control 2-1. inclusion criteria 1. \>19 years old 2. persions who signed the consent form and informed consent in human material research exclusion criteria: 1-2. exclusion criteria 1. patients who have used systemic steroids or antibiotics within the last 1 month 2. patients who have used local steroids or antibiotics within the last 2 weeks 3. patients who have been diagnosed with skin diseases(such as atopic dermatitis) other than hailey-hailey disease 4. patients who are unable to swab or who may have affect a medical condition 5. patients who have difficulty making clear decisions due to lack of decision-making ability 6. in addition to the above, a person who is considered inappropriate to participate in this study, such as collecting test information, based on the medical judgment of the principal investigator or subinvestigator. 2-2. exclusion criteria 1. persions who have skin diseases(such as atopic dermatitis) or diseases affecting the skin microbes 2. persions who have used systemic steroids or antibiotics within the last 1 month 3. patients who have used local steroids or antibiotics within the last 2 weeks 4. in addition to the above, a person who is considered inappropriate to participate in this study, such as collecting test information, based on the medical judgment of the principal investigator or subinvestigator.
ultrasound-based diagnostic model for differentiating malignant breast lesion from benign lesion

Conditions: Breast Cancer Female; Diagnoses Disease

Summary: this study proposed to construct an ultrasound-based diagnostic model for differentiating malignant breast lesion from benign lesion. this study contains both retrospective and prospective part, which are designed for model construction and independent validation, respectively.this study aims to construct an easy-to-use ultrasound-based model, prove the efficacy of the model for identifying malignant breast lesion from benign lesion, and finally promote the application of this diagnostic model in more clinics.


Eligibility criteria:
inclusion criteria: * female * with single breast lesion(maximum diameter\>0.8 cm) * agree to receive follow-up in six months and take the second breast ultrasound six month after the first breast ultrasound, if a benign diagnosis is achieved at the first ultrasound * sign the informed consent exclusion criteria: * lost to follow-up * failed to take the second breast ultrasound six month after the first breast ultrasound
study of rns60 on pain and function after hip labral repair

Conditions: Hip Labral Tear

Summary: the purpose of this study is to see if use of rns60 during hip labral repair surgery decreases pain and improves functional capacity post-operation.


Eligibility criteria: